Trial results

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

NCT07446998 on ClinicalTrials.gov · last registry update 2026-07-01

Recruiting now, toward 200 participants. Due to report October 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

RECRUITING

Phase

P2

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Veru Inc.

Sponsor type

Industry

Enrollment

200

Started

2026-03-26

Primary completion

2027-10 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone.

Conditions studied

Obesity & Overweight · Mobility Disability · HOMA-IR

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.